Kang Zhang: h-index, Total Citations, and Citation Map
Kang Zhang's h-index is 121 (500 i10-index, 98,211+ total citations across 1,000+ publications) according to Google Scholar as of August 2026. Kang Zhang is affiliated with Macau University of Science and Technology.
Kang Zhang is a researcher affiliated with Macau University of Science and Technology, specializing in ophthalmology, genomics, stem cell. Their work has been cited 98,211 times. This profile visualizes their global influence, highlighting strong citation networks in United States.
Kang Zhang's Citation Metrics
Bibliometric impact based on 1,000 indexed publications.
- H-Index
- 121
- i10-Index
- 500
- Total Citations
- 98,211
- Citing Countries
- 33
As of August 2026.
Kang Zhang has an h-index of 121 and 98,211 total citations across 1000 publications, with research cited by institutions in 33 countries.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Ranibizumab for neovascular age-related macular degeneration
20067,541
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Significant Contributions
Auto-detected research lines — a seminal paper and the follow-up work building on it. Review and edit before using in a petition. Each Free PDF opens in a new tab — EB-1A organises this into the structure USCIS applies to Criterion 5 of 8 CFR § 204.5(h)(3)(v); EB-1B re-frames it under § 204.5(i)(3) (outstanding researcher); NIW presents it under prong 2 of Matter of Dhanasar.
The researcher published a seminal 2006 study on ranibizumab for neovascular age-related macular degeneration, which has garnered over 7,500 citations and established a critical benchmark in ophthalmic treatment.
The researcher conducted a pivotal comparative study evaluating ranibizumab versus verteporfin for neovascular age-related macular degeneration, establishing a critical benchmark in ophthalmic treatment efficacy.
The researcher established a quantitative framework for assessing human aging rates through genome-wide methylation profiling, a seminal contribution evidenced by over 4,600 citations.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
About Kang Zhang's research
Kang Zhang is a researcher in ophthalmology, genomics and stem cell at Macau University of Science and Technology. Their work has been cited 98,211 times across 1,000 publications (h-index 121), according to Google Scholar.
Their most-cited work, “Ranibizumab for neovascular age-related macular degeneration” (2006), has accumulated 7,541 citations. Other influential works include “Ranibizumab for neovascular age-related macular degeneration” (2006) with 7,541 citations and “Identifying medical diagnoses and treatable diseases by image-based deep learning” (2018) with 5,731 citations.
Citations of Kang Zhang's research come primarily from United States, China and United Kingdom, reflecting international research impact across 5+ countries. The interactive citation map above shows the full geographic distribution of the institutions citing this work.
